The global IVD market is undergoing its most significant technology transition since the automation wave of the 1990s. Artificial intelligence is being embedded into analyzer workflows, image analysis, and result interpretation. Next-generation sequencing is moving from research into routine clinical use. Digital pathology and whole slide imaging are replacing glass slides in anatomic pathology. Point-of-care molecular testing — driven by Abbott's ID NOW, Cepheid's GeneXpert, and bioMérieux's BIOFIRE — is decentralizing infectious disease diagnosis. And liquid biopsy is creating an entirely new segment at the intersection of IVD and oncology. The world's 10 leading IVD suppliers are deploying these technologies through organic development, targeted M&A, and strategic partnerships with AI companies, hospital networks, and pharmaceutical manufacturers.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Emerging Technology Assessment — AI, NGS, Liquid Biopsy, Digital Pathology, and Decentralized Testing
• Technology Integration Strategies of the World's 10 Leading Suppliers
• Platform Architecture — Open vs. Closed Systems, Connectivity, and LIS Integration
• AI in IVD — Image Analysis, Result Interpretation, and Workflow Automation
• NGS Clinical Adoption — Oncology, Infectious Disease, and Rare Disease Applications
• Liquid Biopsy — ctDNA, cfRNA, and Multi-Cancer Early Detection
• Strategic Partnership and M&A Patterns in Emerging IVD Technologies
• Investment and Partnership Opportunities
• Strategic Recommendations
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant technology developments 2024-2025
- Highest-priority emerging technology opportunities
- Strategic recommendations
2. IVD Technology Landscape Overview
- Current technology platform map
- Technology disruption drivers
- Investment flows in emerging IVD technologies 2020-2025
- Regulatory pathways for emerging IVD technologies
3. Emerging Technology Deep Dives
- 3.1 Artificial Intelligence and Machine Learning
- 3.2 Next-Generation Sequencing
- 3.3 Liquid Biopsy
- 3.4 Digital Pathology and Whole Slide Imaging
- 3.5 Microfluidics and Lab-on-a-Chip
- 3.6 CRISPR-Based Diagnostics
- 3.7 Digital Health and Connected Diagnostics
- Each section covers: technology maturity and clinical readiness / leading suppliers and competitive landscape / key opportunities and strategic entry points
4. Technology Integration Strategies — The World’s Leading Suppliers
- 4.1 Abbott Diagnostics
- 4.2 Bio-Rad Laboratories
- 4.3 bioMérieux
- 4.4 Danaher (Beckman Coulter, Cepheid, Radiometer)
- 4.5 DiaSorin
- 4.6 Hologic
- 4.7 QuidelOrtho
- 4.8 Roche Diagnostics
- 4.9 Siemens Healthineers
- 4.10 Sysmex
- For each company: integration priorities / key technology programs and milestones / partnership and acquisition activity / competitive positioning by technology segment / integration roadmap through 2030
5. Platform Architecture
- Open vs. closed system strategies
- LIS and EHR integration standards
- Reagent rental and installed base implications
6. Competitive Landscape
- Technology leadership positioning by segment
- M&A and partnership activity in emerging technologies 2023-2025
- New entrants and disruptors challenging established suppliers
7. Regional Adoption of Emerging Technologies
- 7.1 North America (U.S., Canada, Mexico)
- 7.2 Europe (38 countries)
- 7.3 Asia-Pacific (18 countries)
- 7.4 Latin America (22 countries)
- 7.5 Middle East (11 countries)
- 7.6 Africa and Rest of World
8. Investment and Partnership Opportunities
- Technology licensing and acquisition targets
- Joint venture and partnership opportunities
- Startup and emerging company ecosystem
9. Strategic Conclusions and Recommendations
- Highest-priority emerging technology opportunities by segment
- Build vs. buy vs. partner framework
- Key licensing, partnership and acquisition targets
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. IVD Emerging Technologies — Technology Maturity Assessment by Application 2025
Table 2. Artificial Intelligence in IVD — Application Landscape and Leading Suppliers 2025
Table 3. Next-Generation Sequencing — Application Landscape and Leading Suppliers 2025
Table 4. Liquid Biopsy — Technology Platform and Leading Suppliers 2025
Table 5. Digital Pathology — Platform Comparison and Leading Suppliers 2025
Table 6. Microfluidics and Lab-on-a-Chip — Technology Status and Leading Suppliers 2025
Table 7. World’s Leading Suppliers — Emerging Technology Investment and Strategy
Table 8. World’s Leading Suppliers — M&A in Emerging Technologies 2023-2025
Table 9. World’s Leading Suppliers — Technology Portfolio and Platform Architecture
Table 10. IVD Startup and Venture Capital Ecosystem — Key Companies and Investment Themes
Table 11. IVD Emerging Technologies — Investment Opportunity Assessment by Technology
Table 12. IVD Emerging Technologies — Key Risks and Mitigation Strategies
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
